TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Launched by TECLISON LTD. · Jan 7, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with advanced colorectal cancer or lung cancer that has spread to the liver. The treatment combines a procedure called Trans-arterial Tirapazamine Embolization with a medication called Pembrolizumab. This trial aims to see if this combination can help patients who have not responded to other treatments.

To participate, patients should be between the ages of 65 and 74 and have specific types of cancer: either colorectal cancer that has progressed after at least two types of standard chemotherapy or lung cancer that has not improved after chemotherapy and an immunotherapy treatment. Participants should have measurable disease and good overall health. They will need to have had a break from previous chemotherapy for at least four weeks before starting the trial. This study is currently recruiting participants, and it’s important for anyone considering joining to discuss it with their healthcare provider to understand the potential benefits and risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations
• • mCRC progressed on at least two lines of standard chemotherapy; or
• • NSCLC progressed on chemotherapy and an immune checkpoint inhibitor
• • Measurable disease
• • ECOG 0-1
• • At least 4 weeks from prior chemotherapy and free from chemo-related toxicity
• • Adequate organ function
• Exclusion Criteria:
• • Prior organ transplantation
• • Liver metastasis more than 50%
• • Oxygen saturation less than 92% in room air
• • Prior autoimmune disorder
• • CNS metastasis
• • Major GI bleeding in the last 2 months